Cancer Research

Working Toward a Cure

Studies to advance immunotherapy and breakthroughs in cancer treatment.

Current Trials

Bladder Cancer

Cysview

Description

The purpose of the study is to gather more information on the current use of Blue Light Cystoscopy with Cysview® in urologists' practices. This trial is a registry study for patients with bladder cancer who undergo cystoscopy. Cysview is an FDA approved drug imaging agent that is absorbed by malignant cells causing them to appear pink under blue light thus making them easier to see.

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 5/20/2022

Location: Lexington Urology

Breast Cancer

A011801

Description
The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase Iii Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1 And Tucatinib.

This trial studies how well trastuzumab emtanzine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Giving T-DMI and tucatinib together may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. 

Open to enrollment 

Posted By: Dr. Steven Madden

Posted Date: 9/27/2019

Location:

AFT 25/ Comet

Description
Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial

Open to enrollment 

Posted By: Dr. Steven Madden

Posted Date: 11/9/2020

Location: Lexington Oncology

MA.39 Tailor RT

Description
A randomized trial of regional radiotherapy in biomarker low risk node positive breast cancer.

Posted By: Dr. Davis

Posted Date: 9/5/2019

Location: Lexington Radiation Oncology

Head & Neck Cancer

A071801

Description

This study is being done to answer the following question: does fractionated (multiple treatment sessions) radiosurgery delivered to the surgical cavity in the brain (the part of the brain where the brain metastasis was resected) decrease the risk of tumor recurring in the surgical cavity compared to single fraction (single treatment session) radiosurgery?

Open to enrollment

Posted By: Dr. Quillin Davis

Posted Date: 11/1/2021

Location: Lexington Oncology

Lung Cancer

Emerge 402

Description
Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Open to enrollment

Posted By: Dr. Steven Madden

Posted Date: 11/1/2021

Location: Lexington Oncology

Alchemist - A151216

Description
Genetic Testing For Patients with Resectable or Resected Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial 

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 3/15/2015

Location: Lexington Oncology

Alchemist - E4512

Description
Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 5/16/2016

Location: Lexington Oncology

Prostate Cancer

VERACITY-V3011102

Description
Randomized, Active-Controlled, Phase 3 Study of VERU111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Prior Treatment with at Least One Androgen Receptor Targeting Agent.

Open to enrollment

Posted By: Dr. Steven Madden

Posted Date: 2/21/2022

Location:

BRAT

Description
The purpose of the Prostate BRAchyTherapy (BRAT) Registry is to measure clinical outcomes of patients treated with Brachytherapy at Lexington Medical Center (LMC).

Open to enrollment

Posted By: Dr. Quillin Davis

Posted Date: 11/1/2021

Location: Lexington Oncology

EA8184

Description
To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring.

This study is being done to answer the following question:  Can we lower the chance of your prostate cancer growing by adding Sunphenon® 90D (containing green tea catechins) by closely monitoring your prostate cancer?

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 11/1/2021

Location: Lexington Urology